The world’s largest pharmaceuticals maker, Valeant Pharmaceuticals, reported a record profit in its fourth quarter and said it is considering an exit from Canada and the U.S.
The company said on Friday that it is reviewing its Canadian operations, as well as the U,S., as it looks for other opportunities.
Valeant said its revenue for the fiscal fourth quarter was up 2% year-over-year to $7.7 billion.
Valeante has seen its stock surge to more than $400 from $70 last year.
Valeants shares rose more than 7% in after-hours trading.
Valeantes shares are up over 14% in the past 12 months.
Valeanta shares are down about 4% in value.
Shares of Valeant have also been battered by the news that Valeant will shut down its Canadian pharmacy operations in 2017 and 2018, according to the Wall Street Times.
The company said that it has no plans to restructure its business, but is evaluating a range of options.